Phibro Animal Health Corporation (PAHC) fair value analysis

Nasdaq · Updated 2026-09-07

Phibro Animal Health Corporation is a company that develops, manufactures, and distributes products for animal health and nutrition. The company operates globally, serving customers in livestock, poultry, and aquaculture industries across multiple regions.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, PAHC is trading at a 10–25% discount to estimated fair value.

PAHC currently ranks #42 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $37.15
Sector: Healthcare
12-month range: $29.76–$54.68

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Momentum grade: A
Leverage: High
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The lower-middle quarter of its range

What our data shows for PAHC

Our model validated 17 trailing price-to-earnings windows for PAHC, built from quarterly earnings records.
Shares are trading in the lower third of their 12-month price range of $29.76–$54.68.
The 14-day relative strength index sits at a neutral 59.
4 of the last 12 weekly snapshots showed positive price momentum.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for PAHC
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent PAHC news

TickrTrends' derived news-sentiment signal for PAHC is currently leaning positive, computed from recent coverage.

Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year (finance.yahoo.com, 2026-09-01)
TickrTrends take: Phibro Animal Health has now completed its first full year following a significant acquisition, providing investors with the initial results needed to assess whether the company paid a fair price for the deal. Given TickrTrends' current assessment that PAHC trades at an undervalued level, readers should monitor whether the acquired assets generate sufficient earnings and cash flow to justify the acquisition price and support any multiple expansion. The healthcare sector investor watching this stock should track whether management's integration efforts translate into margin improvements or revenue synergies that could narrow any valuation gap.
Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year (insidermonkey.com, 2026-09-01)
TickrTrends take: Phibro Animal Health Corporation has completed its first full year following a significant acquisition, providing investors with their first comprehensive view of how the combined entity is performing operationally and financially. TickrTrends currently identifies PAHC as undervalued within the Healthcare sector, suggesting that market pricing may not yet fully reflect the integration progress or earnings potential from this major deal. Valuation-focused readers should monitor whether upcoming quarterly results demonstrate that the acquisition is delivering expected synergies and revenue growth, which could validate or challenge the current undervalued assessment.
Phibro Animal Health Corporation 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:PAHC) 2026-08-31 (seekingalpha.com, 2026-08-31)
TickrTrends take: Phibro Animal Health Corporation's latest quarterly results come as TickrTrends currently assesses the stock as undervalued within the Healthcare sector, suggesting the market may not be fully pricing in the company's earnings performance. Investors focused on valuation metrics should examine whether the company's recent financial results support the undervalued designation or indicate changing fundamentals that warrant recalibration. The earnings call presentation provides an opportunity to evaluate management's guidance and operational efficiency against the current market valuation.

What people are saying

Follow the PAHC conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' momentum indicator for PAHC improved significantly this week, moving from a D rating to an A rating. This substantial upgrade reflects strengthened price momentum in the healthcare sector stock. The current valuation verdict remains Undervalued.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is PAHC stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), PAHC is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is PAHC's TickrTrends verdict?

PAHC's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does PAHC compare to other Healthcare stocks?

PAHC ranks #42 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is PAHC overbought or oversold?

PAHC's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

PAHC vs ABT · PAHC vs BTSG · PAHC vs COLL · PAHC vs DVA · PAHC vs EXEL